| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76f2bd75ec5ba1bdcb10cd0e3f3ec2e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59e0ea6512115355f477811bc2b2154a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1101d4c67a6e237a2d1d5d2c0277174b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d6be134708b065b3adb1095fc5f26aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_914b1fc0727f18807386d94c9020038c |
| publicationDate |
2019-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019063758-A1 |
| titleOfInvention |
METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND |
| abstract |
The present invention relates to biomarkers associated with the clinical response to a FGF-18 compound prior to or during the treatment of a cartilage disorder. The present invention more specifically relates to specific proteins present in blood, serum, synovial fluid or urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further relates to specific proteins that are associated with a cartilage response to FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used to predict the response to treatment with FGF-18 before starting treatment with FGF-18 or during treatment. It can be used to select / identify subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnoses could lead to increased benefit and reduced risk in subjects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111163791-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11467169-B2 |
| priorityDate |
2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |